Cargando…
Can the Gleason score be predicted in patients with prostate cancer? A dynamic contrast-enhanced MRI, ((68))Ga-PSMA PET/CT, PSA, and PSA-density comparison study
PURPOSE: The present study aims to evaluate whether perfusion parameters in prostate magnetic resonance imaging (MRI), ((68))Ga-prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT), prostate-specific antigen (PSA), and PSA density can be used to predi...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Galenos Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679545/ https://www.ncbi.nlm.nih.gov/pubmed/37395389 http://dx.doi.org/10.4274/dir.2023.232186 |
_version_ | 1785150600750563328 |
---|---|
author | Akkaya, Hüseyin Dilek, Okan Özdemir, Selim Taş, Zeynel Abidin Öztürk, İhsan Sabri Gülek, Bozkurt |
author_facet | Akkaya, Hüseyin Dilek, Okan Özdemir, Selim Taş, Zeynel Abidin Öztürk, İhsan Sabri Gülek, Bozkurt |
author_sort | Akkaya, Hüseyin |
collection | PubMed |
description | PURPOSE: The present study aims to evaluate whether perfusion parameters in prostate magnetic resonance imaging (MRI), ((68))Ga-prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT), prostate-specific antigen (PSA), and PSA density can be used to predict the lesion grade in patients with prostate cancer (PCa). METHODS: The study included a total of 137 PCa cases in which 12-quadrant transrectal ultrasound-guided prostate biopsy (TRUSBx) was performed, the Gleason score (GS) was determined, and pre-biopsy multiparametric prostate MRI and ((68))Ga-PSMA PET/CT examinations were undertaken. The patient population was evaluated in three groups according to the GS: (1) low risk; (2) intermediate risk; (3) high risk. The PSA, PSA density, pre-TRUSBx ((68))Ga-PSMA PET/CT maximum standardized uptake value (SUV(max)), perfusion MRI parameters [maximum enhancement, maximum relative enhancement, T0 (s), time to peak (s), wash-in rate (s(-1)), and wash-out rate (s(-1))] were retrospectively evaluated. RESULTS: There was no significant difference between the three groups in relation to the PSA, PSA density, and ((68))Ga-PSMA PET/CT SUV(max) (P > 0.05). However, the values of maximum enhancement, maximum relative enhancement (%), T0 (s), time to peak (s), wash-in rate (s(-1)), and wash-out rate (s(-1)) significantly differed among the groups. A moderate positive correlation was found among the prostate volume, PSA (r = 0.490), and ((68))Ga-PSMA SUV(max) (r = 0.322) in the patients. The wash-out rate (s(-1)) and wash-in rate (s(-1)) had the best diagnostic test performance (area under the curve: 89.1% and 78.4%, respectively). CONCLUSION: No significant correlation was found between the ((68))Ga-PSMA PET/CT SUV(max) and the GS. The wash-out rate was more successful in estimating the pretreatment GS than the ((68))Ga-PSMA PET/CT SUV(max). |
format | Online Article Text |
id | pubmed-10679545 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Galenos Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-106795452023-12-05 Can the Gleason score be predicted in patients with prostate cancer? A dynamic contrast-enhanced MRI, ((68))Ga-PSMA PET/CT, PSA, and PSA-density comparison study Akkaya, Hüseyin Dilek, Okan Özdemir, Selim Taş, Zeynel Abidin Öztürk, İhsan Sabri Gülek, Bozkurt Diagn Interv Radiol Abdominal Imaging - Original Article PURPOSE: The present study aims to evaluate whether perfusion parameters in prostate magnetic resonance imaging (MRI), ((68))Ga-prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT), prostate-specific antigen (PSA), and PSA density can be used to predict the lesion grade in patients with prostate cancer (PCa). METHODS: The study included a total of 137 PCa cases in which 12-quadrant transrectal ultrasound-guided prostate biopsy (TRUSBx) was performed, the Gleason score (GS) was determined, and pre-biopsy multiparametric prostate MRI and ((68))Ga-PSMA PET/CT examinations were undertaken. The patient population was evaluated in three groups according to the GS: (1) low risk; (2) intermediate risk; (3) high risk. The PSA, PSA density, pre-TRUSBx ((68))Ga-PSMA PET/CT maximum standardized uptake value (SUV(max)), perfusion MRI parameters [maximum enhancement, maximum relative enhancement, T0 (s), time to peak (s), wash-in rate (s(-1)), and wash-out rate (s(-1))] were retrospectively evaluated. RESULTS: There was no significant difference between the three groups in relation to the PSA, PSA density, and ((68))Ga-PSMA PET/CT SUV(max) (P > 0.05). However, the values of maximum enhancement, maximum relative enhancement (%), T0 (s), time to peak (s), wash-in rate (s(-1)), and wash-out rate (s(-1)) significantly differed among the groups. A moderate positive correlation was found among the prostate volume, PSA (r = 0.490), and ((68))Ga-PSMA SUV(max) (r = 0.322) in the patients. The wash-out rate (s(-1)) and wash-in rate (s(-1)) had the best diagnostic test performance (area under the curve: 89.1% and 78.4%, respectively). CONCLUSION: No significant correlation was found between the ((68))Ga-PSMA PET/CT SUV(max) and the GS. The wash-out rate was more successful in estimating the pretreatment GS than the ((68))Ga-PSMA PET/CT SUV(max). Galenos Publishing 2023-09-05 /pmc/articles/PMC10679545/ /pubmed/37395389 http://dx.doi.org/10.4274/dir.2023.232186 Text en © Copyright 2023 by Turkish Society of Radiology | Diagnostic and Interventional Radiology, published by Galenos Publishing House. https://creativecommons.org/licenses/by-nc/4.0/Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. (https://creativecommons.org/licenses/by-nc/4.0/) |
spellingShingle | Abdominal Imaging - Original Article Akkaya, Hüseyin Dilek, Okan Özdemir, Selim Taş, Zeynel Abidin Öztürk, İhsan Sabri Gülek, Bozkurt Can the Gleason score be predicted in patients with prostate cancer? A dynamic contrast-enhanced MRI, ((68))Ga-PSMA PET/CT, PSA, and PSA-density comparison study |
title | Can the Gleason score be predicted in patients with prostate cancer? A dynamic contrast-enhanced MRI, ((68))Ga-PSMA PET/CT, PSA, and PSA-density comparison study |
title_full | Can the Gleason score be predicted in patients with prostate cancer? A dynamic contrast-enhanced MRI, ((68))Ga-PSMA PET/CT, PSA, and PSA-density comparison study |
title_fullStr | Can the Gleason score be predicted in patients with prostate cancer? A dynamic contrast-enhanced MRI, ((68))Ga-PSMA PET/CT, PSA, and PSA-density comparison study |
title_full_unstemmed | Can the Gleason score be predicted in patients with prostate cancer? A dynamic contrast-enhanced MRI, ((68))Ga-PSMA PET/CT, PSA, and PSA-density comparison study |
title_short | Can the Gleason score be predicted in patients with prostate cancer? A dynamic contrast-enhanced MRI, ((68))Ga-PSMA PET/CT, PSA, and PSA-density comparison study |
title_sort | can the gleason score be predicted in patients with prostate cancer? a dynamic contrast-enhanced mri, ((68))ga-psma pet/ct, psa, and psa-density comparison study |
topic | Abdominal Imaging - Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679545/ https://www.ncbi.nlm.nih.gov/pubmed/37395389 http://dx.doi.org/10.4274/dir.2023.232186 |
work_keys_str_mv | AT akkayahuseyin canthegleasonscorebepredictedinpatientswithprostatecanceradynamiccontrastenhancedmri68gapsmapetctpsaandpsadensitycomparisonstudy AT dilekokan canthegleasonscorebepredictedinpatientswithprostatecanceradynamiccontrastenhancedmri68gapsmapetctpsaandpsadensitycomparisonstudy AT ozdemirselim canthegleasonscorebepredictedinpatientswithprostatecanceradynamiccontrastenhancedmri68gapsmapetctpsaandpsadensitycomparisonstudy AT taszeynelabidin canthegleasonscorebepredictedinpatientswithprostatecanceradynamiccontrastenhancedmri68gapsmapetctpsaandpsadensitycomparisonstudy AT ozturkihsansabri canthegleasonscorebepredictedinpatientswithprostatecanceradynamiccontrastenhancedmri68gapsmapetctpsaandpsadensitycomparisonstudy AT gulekbozkurt canthegleasonscorebepredictedinpatientswithprostatecanceradynamiccontrastenhancedmri68gapsmapetctpsaandpsadensitycomparisonstudy |